Literature DB >> 2189900

Third generation cephalosporins: safety profiles after 10 years of clinical use.

H C Neu1.   

Abstract

Compared with aminoglycosides, chloramphenicol, sulfonamides, tetracyclines, and even penicillins, the cephalosporins represent a remarkably safe class of antibiotics. Among the cephalosporins, the extended spectrum, third generation agents developed generally produce few side effects and appear to be less allergenic than the penicillins. Nephrotoxicity has not been a problem at recommended doses. Some third generation agents can cause hypoprothrombinemia if not administered with vitamin K, and disulfiram-like reactions occur with some agents because of the presence of a thiomethyl tetruzole moiety affixed to the cephem nucleus. There is a greater incidence of diarrhea associated with the agents excreted through a primarily biliary route, and this may contribute to the selection of drug resistant bacteria. Some agents are less active against staphylococci and their use may result in an increased incidence of superinfection or overgrowth of enterococci. If attention is given to the potential for adverse effects, many of these problems can be avoided and the third generation cephalosporins can be used safely in hospitals, nursing homes, and home care settings.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189900     DOI: 10.1002/j.1552-4604.1990.tb03476.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

1.  Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

Authors:  S K Nath; G A Foster; L A Mandell; C Rotstein
Journal:  Can J Infect Dis       Date:  1995-01

Review 2.  Pharmacological properties of cephalosporins.

Authors:  W Christ
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 3.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 4.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

5.  Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.

Authors:  Elsa Maksoud; Berengere Koehl; Aude Facchin; Phuong Ha; Wei Zhao; Florentia Kaguelidou; Malika Benkerrou; Patricia Mariani; Albert Faye; Mathie Lorrot; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Cefotaxime desensitization.

Authors:  G Papakonstantinou; J R Bogner; F Hofmeister; R Hehlmann
Journal:  Clin Investig       Date:  1993-02

Review 7.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

8.  Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.

Authors:  A G Maiche; L Teerenhovi
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 9.  Efficacy and safety of cefotaxime in the management of pediatric infections.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 10.  Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

Authors:  H C Neu
Journal:  Infection       Date:  1991       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.